The Effect of BIA 2-093 on the Steady-state Pharmacodynamic and Pharmacokinetic Profiles of Warfarin
NCT02287415 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 13
Last updated 2014-12-01
Summary
Multiple-dose, open-label, single-period study consisting of three consecutive phases
Conditions
Interventions
- DRUG
-
BIA 2-093
- DRUG
-
Warfarin
Sponsors & Collaborators
-
Bial - Portela C S.A.
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 45 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2002-05-31
- Primary Completion
- 2002-07-31
- Completion
- 2002-07-31
More Related Trials
-
A Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic Profile and CNS Effects of BIA 2-093
NCT02171234 ·Status: COMPLETED ·Phase: PHASE1
-
The Tolerability and Effect of Food on the Pharmacokinetics of a Single 800 mg Oral Dose of BIA 2-093
NCT02170649 ·Status: COMPLETED ·Phase: PHASE1
-
A Single Centre, Phase I, Double-blind, Randomised, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetic Profile and Effects on EEG of Single Rising Oral Doses of BIA 2-093
NCT02171195 ·Status: COMPLETED ·Phase: PHASE1
-
An Open-label, Single-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093
NCT02281422 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics, Efficacy and Tolerability of BIA 2-093
NCT02170064 ·Status: COMPLETED ·Phase: PHASE2
-
The Effect of BIA 2-093 on the Steady-state Pharmacokinetic Profile of Phenytoin in Patients
NCT01878578 ·Status: TERMINATED ·Phase: PHASE1
-
A Study on the Effects of Valproate on the Pharmacokinetics of RO4917838 in Healthy Volunteers
NCT01495104 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial Epilepsy
NCT00957047 ·Status: COMPLETED ·Phase: PHASE3
-
Tolerability and Pharmacokinetics of a Single 900 mg Oral Dose of BIA 2-093 and Oxcarbazepine in Healthy Volunteers
NCT01678976 ·Status: COMPLETED ·Phase: PHASE1
-
Open-label Drug Interaction Study Between Eslicarbazepine Acetate and Phenytoin.
NCT02283827 ·Status: COMPLETED ·Phase: PHASE1
-
A Sequential Multiple Ascending Dose Study of the Safety and Pharmacokinetics of Eslicarbazepine Acetate in Adult Healthy Volunteers
NCT01879332 ·Status: COMPLETED ·Phase: PHASE1
-
A Placebo-controlled Study to Investigate Safety and Efficacy of BIA 2-093
NCT02170077 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate the Effect of UGT Inhibition by Valproic Acid on the Pharmacokinetics of BIIB074
NCT03385525 ·Status: COMPLETED ·Phase: PHASE1
-
Disposition of Eslicarbazepine Acetate and Its Metabolites S-licarbazepine and R-licarbazepine
NCT02281591 ·Status: COMPLETED ·Phase: PHASE1
-
A Clinical Study of Belzutifan (MK-6482) Alone or With Phenytoin in Healthy Participants (CA46602/MK-6482-035)
NCT06903715 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Safety and Tolerability of Valproic Acid in Trauma Patients(Part 2)
NCT02872428 ·Status: TERMINATED ·Phase: PHASE1
-
Effects of Eslicarbazepine Acetate (Esl, Bia 2-093) on Cognitive Function in Children With Partial Onset Seizures
NCT01527513 ·Status: COMPLETED ·Phase: PHASE2
-
A Open-label, Drug Interaction Study Between Eslicarbazepine Acetate and Topiramate
NCT02283814 ·Status: COMPLETED ·Phase: PHASE1
-
Characterization of Epilepsy Patients BEEP 2b
NCT02707965 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate Pharmacokinetics and Tolerability of Multiple Doses of Eslicarbazepine Acetate and Oxcarbazepine
NCT00900237 ·Status: COMPLETED ·Phase: PHASE1
-
Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization
NCT02283788 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Gliclazide in Healthy Volunteers
NCT02777671 ·Status: COMPLETED ·Phase: PHASE1
-
Valproic AcId for Traumatic BRAin INjury Trial
NCT07166393 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2/PHASE3
-
Dosage Form Proportionality of Opicapone To-Be-Marketed Formulation
NCT02305329 ·Status: COMPLETED ·Phase: PHASE1
-
Trial of Oral Valproic Acid for Retinitis Pigmentosa
NCT01233609 ·Status: COMPLETED ·Phase: PHASE2